INO · Inovio Pharmaceuticals, Inc. · Documents
$0.95
+0.02 (+1.97%)
At close · Oct 29
View the 10-K filed Mar 12, 2026
Return incl. dividend (before tax)
Q2 2026 earnings call transcript
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— key customers 100% of revenue
Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$96.01M
Shares
103.40M
Volume · Oct 29
218.39K
Avg daily vol (3M)
4.53M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2020-06-25 | 2020-06-19 | |
| 8-K | — | 2020-06-03 | — | |
| 8-K | — | 2020-05-18 | 2020-05-14 | |
| 8-K | — | 2020-05-12 | — | |
| 10-Q | — | 2020-05-11 | 2020-03-31 | |
| DEFA14A | — | 2020-04-15 | — | |
| 8-K | — | 2020-04-06 | — | |
| 8-K | — | 2020-04-03 | — | |
| DEF 14A | — | 2020-03-27 | 2019-12-31 | |
| S-3 | — | 2020-03-13 | — | |
| 10-K | — | 2020-03-12 | 2019-12-31 | |
| 8-K | — | 2020-03-09 | 2020-03-03 | |
| 8-K | — | 2020-02-07 | — | |
| S-3 | — | 2020-01-31 | — | |
| 8-K | — | 2020-01-15 | — | |
| 8-K | — | 2020-01-02 | 2019-12-26 |
Showing 101–116 of 116 filings
Key facts
CIK
1055726
CUSIP
45773H409
13F (30d)
22 filings
22 filers
Visit website
Investor relations